These ASX 200 shares could be buys if there's a stock market crash in 2025

I'm optimistic that the S&P/ASX 200 Index (ASX: XJO) will continue to break records in 2025.

But unfortunately, it is impossible to know what will happen with any certainty.

And while a stock market crash would be disappointing next year, I think it is important not to fear such an event. Instead, investors should see a crash as an opportunity to load up on high-quality ASX 200 shares at good prices.

With that in mind, let's take a look at a couple of ASX 200 shares that could be strong buys if the market pulled back. They are as follows:

Life360 Inc (ASX: 360)

The first ASX 200 share that could be a buy if the stock market crashes is Life360.

It is a growing family connection and safety company that aims to keep people close to the ones they love. Its category-leading mobile app, the Life360 app, provides location sharing, safe driver reports, and crash detection with emergency dispatch to a massive 76.9 million monthly active users (MAU) across more than 170 countries.

Bell Potter is bullish on the company and believes it is well-placed for long-term growth. Its analysts recently said:

Life360 operates a market-leading app that provides communication, driving safety, and location-sharing features. With over 70 million monthly active users and 2 million paying circles, the company has significant growth potential as it continues to rapidly monetise its customer base.

Bell Potter currently has a buy rating and $26.75 price target on its shares.

Pro Medicus Limited (ASX: PME)

Pro Medicus could be an ASX 200 share to buy in the event of a stock market crash. It is a leading health imaging technology provider, delivering services and solutions to hospitals, imaging centres, and healthcare groups worldwide.

Goldman Sachs is a big fan of the company and believes it has a significant long-term opportunity. It recently said:

We remain positive on the PME equity story as one of Australia's best global growth companies. […] PME is not cheap, trading on 114x FY26E EV/EBITDA, but we highlight its revenue/margin outlook, unique cloud offering, and significant long-term opportunity. Additionally, with a focus on the US regulatory outlook, we believe MedTech is increasingly being evaluated as a safe haven within healthcare as it is generally more insulated from impending policy volatility.

Goldman Sachs currently has a buy rating and $278.00 price target on its shares.